| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 5699234 | Clinical Oncology | 2011 | 5 Pages |
Abstract
In patients with mRCC, a high baseline 18F-FDG uptake indicates aggressive disease, and the degree of reduction in 18F-FDG uptake after sunitinib treatment adds valuable prognostic information. Hence, the inclusion of PET results seems to improve the clinical counselling of patients with mRCC. Larger studies are needed to confirm these findings.
Keywords
Related Topics
Health Sciences
Medicine and Dentistry
Oncology
Authors
M.E. Revheim, A.K. Winge-Main, G. Hagen, J.G. Fjeld, S.D. Fosså, W. Lilleby,